Sarah Onuora
doi : 10.1038/s41584-020-00559-x
Volume 17, Issue 1, January 2021, Published 01 December 2020
Sarah Onuora
doi : 10.1038/s41584-020-00554-2
Volume 17, Issue 1, January 2021, Published 02 December 2020
Sarah Onuora
doi : 10.1038/s41584-020-00555-1
Volume 17, Issue 1, January 2021, Published 02 December 2020
Sarah Onuora
doi : 10.1038/s41584-020-00556-0
Volume 17, Issue 1, January 2021, Published 02 December 2020
Sarah Onuora
doi : 10.1038/s41584-020-00557-z
Volume 17, Issue 1, January 2021, Published 02 December 2020
Jessica McHugh
doi : 10.1038/s41584-020-00558-y
Volume 17, Issue 1, January 2021, Published 01 December 2020
Sarah Onuora
doi : 10.1038/s41584-020-00547-1
Volume 17, Issue 1, January 2021, Published 20 November 2020
Joanna Clarke
doi : 10.1038/s41584-020-00542-6
Volume 17, Issue 1, January 2021, Published 10 November 2020
Jessica McHugh
doi : 10.1038/s41584-020-00553-3
Volume 17, Issue 1, January 2021, Published 02 December 2020
Joanna Clarke
doi : 10.1038/s41584-020-00548-0
Volume 17, Issue 1, January 2021, Published 20 November 2020
Darren Plant & Anne Barton
doi : 10.1038/s41584-020-00538-2
Volume 17, Issue 1, January 2021, Published 12 November 2020
The ability to predict how a patient might respond to a medication would shift treatment decisions away from trial and error and reduce disease-associated health and financial burdens. Machine learning approaches applied to genomic datasets offer great promise to deliver personalized medicine but their application must first be optimized.
Guillermo J. Pons-Estel & Graciela S. Alarc?n
doi : 10.1038/s41584-020-00545-3
Volume 17, Issue 1, January 2021, Published 30 November 2020
The new 2019 EULAR–ACR classification criteria for systemic lupus erythematosus (SLE) performed well in the initial derivative and validation cohorts. But do these criteria outperform previous classification criteria across sexes, disease durations or ethnicities?
Kirsten Minden
doi : 10.1038/s41584-020-00534-6
Volume 17, Issue 1, January 2021, Published 30 October 2020
For young people with rheumatic diseases, the transition from paediatric to adult rheumatology care is a vulnerable time, and delays or disruption in their care can lead to adverse outcomes. Research into the factors associated with gaps in transitional care could improve the identification and targeting of vulnerable groups.
Eloisa Bonf?, Laure Gossec, David A. Isenberg, Zhanguo Li & Soumya Raychaudhuri
doi : 10.1038/s41584-020-00527-5
Volume 17, Issue 1, January 2021, Published 02 November 2020
The COVID-19 pandemic led to unprecedented changes in rheumatology clinical practice. In this Viewpoint article, we asked five experts to describe their experiences of the COVID-19 pandemic, how their clinical practice has changed, and the opportunities and challenges that lie ahead.
Maya H. Buch, Stephen Eyre & Dennis McGonagle
doi : 10.1038/s41584-020-00541-7
Volume 17, Issue 1, January 2021, Published 08 December 2020
Refractory rheumatoid arthritis (RA) can present with or without signs of ongoing inflammation. A better understanding of the mechanisms behind refractory RA in the presence and absence of inflammation could help to improve the treatment of this condition.
Barton L. Wise, Matthias F. Seidel & Nancy E. Lane
doi : 10.1038/s41584-020-00528-4
Volume 17, Issue 1, January 2021, Published 20 November 2020
Nerve growth factor has been investigated as a therapeutic target for osteoarthritis and chronic low back pain, yet worries over adverse effects have stalled drug development. This Review provides an update on the current status of nerve growth factor inhibitors.
Philip R. Coryell, Brian O. Diekman & Richard F. Loeser
doi : 10.1038/s41584-020-00533-7
Volume 17, Issue 1, January 2021, Published 18 November 2020
The development of osteoarthritis (OA) correlates with an increase in the number of senescent cells in joint tissues and the senescence-associated secretory phenotype is implicated in cartilage degradation and OA. Eliminating or altering senescent cells with senolytics or senomorphics could stop OA progression and pathogenesis.
Nigel K. Arden, Thomas A. Perry, Raveendhara R. Bannuru, Olivier Bruyère, Cyrus Cooper, Ida K. Haugen, Marc C. Hochberg, Timothy E. McAlindon, Ali Mobasheri & Jean-Yves Reginster
doi : 10.1038/s41584-020-00523-9
Volume 17, Issue 1, January 2021, Published 28 October 2020
A working group including authors of the latest OARSI and ESCEO recommendations for the management of knee osteoarthritis and independent experts compare and contrast these guidelines, and provide insights into their differences that could help inform application of the recommendations.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟